<p>Virtu Financial LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度收购了 Cytokinetics, Incorporated (NASDAQ:CYTK - 免费报告) 的新股份。该公司收购了 6,433 股生物制药公司的股票，价值约为 303,000 美元。</p>
<ul>
<li>分析师认为仍有时间投资 Edgewise，股价上涨 332%</li>
</ul>
<p>其他一些机构投资者最近也增加或减少了在 CYTK 的持股。Pathstone Holdings LLC 在第三季度将其在 Cytokinetics 的股份增加了 17.0%。Pathstone Holdings LLC 目前拥有 34,560 股生物制药公司的股票，价值 1,825,000 美元，此前在该期间内又收购了 5,027 股。Charles Schwab Investment Management Inc. 在第三季度将其在 Cytokinetics 的股份增加了 42.7%。Charles Schwab Investment Management Inc. 目前拥有 1,321,391 股生物制药公司的股票，价值 69,769,000 美元，此前在上个季度又购买了 395,709 股。制造商人寿保险公司在第三季度将其在 Cytokinetics 的持股增加了 23.6%。制造商人寿保险公司目前拥有 214,832 股生物制药公司的股票，价值 11,343,000 美元，此前在上个季度又购买了 41,057 股。Cynosure Group LLC 在第三季度以 363,000 美元的价值购买了 Cytokinetics 的新股份。最后，MetLife Investment Management LLC 在第三季度将其在 Cytokinetics 的股份增加了 0.4%。MetLife Investment Management LLC 目前拥有 123,308 股生物制药公司的股票，价值 6,511,000 美元，此前在上个季度又购买了 538 股。</p>
<h2>Cytokinetics 股价下跌 1.5%</h2>
<p>周五，CYTK 股票开盘价为 42.99 美元。Cytokinetics, Incorporated 的 52 周低点为 40.53 美元，52 周高点为 75.71 美元。该公司的市值为 50.9 亿美元，市盈率为 -7.99，贝塔系数为 0.95。该公司的速动比率为 9.28，流动比率为 9.28，债务股本比率为 5.93。该公司的 50 日简单移动平均线为 45.80 美元，200 日简单移动平均线为 49.67 美元。</p>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>Cytokinetics (NASDAQ:CYTK - 获取免费报告) 最近于 2 月 27 日星期四发布了季度财报。该生物制药公司报告本季度每股收益为（1.26 美元），超出分析师一致预期的（1.29 美元）0.03 美元。该公司本季度的收入为 1,693 万美元，而分析师预期为 1,426 万美元。平均而言，股票研究分析师预计 Cytokinetics, Incorporated 本年度将发布 -5.24 美元的每股收益。</p>
<h2>Cytokinetics 内部活动</h2>
<p>在其他新闻中，执行副总裁 Andrew Callos 于 3 月 17 日星期一出售了 2,775 股公司的股票。股票以平均价格 44.38 美元出售，总价值为 123,154.50 美元。交易后，执行副总裁现在拥有 34,888 股公司股票，价值约为 1,548,329.44 美元。这笔交易代表其持股减少了 7.37%。该出售在与 SEC 的法律文件中披露，文件可在此链接查看。此外，首席执行官 Robert I. Blum 于 3 月 6 日星期四出售了 16,970 股 Cytokinetics 股票。股票以平均价格 43.44 美元出售，总交易额为 737,176.80 美元。交易后，首席执行官现在拥有 364,181 股公司股票，价值 15,820,022.64 美元。这笔交易代表其持股减少了 4.45%。该出售的披露信息可在此处找到。在上个季度，内部人士共出售了 43,834 股公司股票，价值 1,949,275 美元。公司内部人士持有公司股票的 3.40%。</p>
<h2>分析师设定新目标价</h2>
<p>一些股票研究分析师最近对 CYTK 股票发表了评论。Evercore ISI 在 2 月 7 日星期五的研究报告中将 Cytokinetics 的股票评级提高至 &#34;强力买入&#34;。HC Wainwright 在 2 月 28 日星期五的研究报告中重申了 &#34;买入&#34; 评级，并设定了 120.00 美元的目标价。JMP Securities 在 2 月 7 日星期五的研究报告中重申了 &#34;市场表现优于大盘&#34; 的评级，并对 Cytokinetics 设定了 78.00 美元的目标价。摩根士丹利在 3 月 7 日星期五的研究报告中设定了 Cytokinetics 的目标价为 67.00 美元。最后，Stifel Nicolaus 在 1 月 22 日星期三的报告中开始覆盖 Cytokinetics。他们给予了 &#34;买入&#34; 评级，并设定了 80.00 美元的目标价。两位股票研究分析师对该股票给予了持有评级，十五位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 82.00 美元。</p>
<p><strong>阅读我们关于 CYTK 的最新报告</strong></p>
<h2>Cytokinetics 公司简介</h2>
<p>（免费报告）</p>
<p>Cytokinetics, Incorporated 是一家处于后期阶段的生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗虚弱疾病的方案。该公司主要开发小分子药物候选者，旨在影响肌肉功能和收缩性。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cytokinetics</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Penny Stock SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>能源和石油股票解析</li>
<li>三大饮料股票带来丰厚利润</li>
<li>选举股票：选举如何影响股市</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在细胞动力吗？</h2>
<p>在考虑细胞动力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而细胞动力并不在名单上。</p>
<p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

细胞动力

VIRT

<p>Virtu Financial LLC 在第四季度投资了 303,000 美元于细胞动力，收购了 6,433 股。其他机构投资者也增加了对这家生物制药公司的持股。细胞动力报告的季度每股收益为（$1.26），超出预期，收入为 1,693 万美元。分析师对 CYTK 设置了不同的目标价，评级从 “持有” 到 “强烈买入” 不等。该股票目前交易价格为 42.99 美元，市值为 50.9 亿美元，52 周价格区间为 40.53 美元至 75.71 美元</p>

<p>Virtu Financial LLC acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,433 shares of the biopharmaceutical company's stock, valued at approximately $303,000.</p>
<div class="lb-trans"><p>Virtu Financial LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度收购了 Cytokinetics, Incorporated (NASDAQ:CYTK - 免费报告) 的新股份。该公司收购了 6,433 股生物制药公司的股票，价值约为 303,000 美元。</p>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为仍有时间投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>A number of other institutional investors have also recently added to or reduced their stakes in CYTK. Pathstone Holdings LLC lifted its position in shares of Cytokinetics by 17.0% during the 3rd quarter. Pathstone Holdings LLC now owns 34,560 shares of the biopharmaceutical company's stock valued at $1,825,000 after acquiring an additional 5,027 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Cytokinetics by 42.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company's stock worth $69,769,000 after purchasing an additional 395,709 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Cytokinetics by 23.6% in the third quarter. The Manufacturers Life Insurance Company now owns 214,832 shares of the biopharmaceutical company's stock valued at $11,343,000 after purchasing an additional 41,057 shares during the last quarter. Cynosure Group LLC purchased a new position in shares of Cytokinetics in the third quarter valued at $363,000. Finally, MetLife Investment Management LLC raised its stake in shares of Cytokinetics by 0.4% during the 3rd quarter. MetLife Investment Management LLC now owns 123,308 shares of the biopharmaceutical company's stock worth $6,511,000 after buying an additional 538 shares during the last quarter.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也增加或减少了在 CYTK 的持股。Pathstone Holdings LLC 在第三季度将其在 Cytokinetics 的股份增加了 17.0%。Pathstone Holdings LLC 目前拥有 34,560 股生物制药公司的股票，价值 1,825,000 美元，此前在该期间内又收购了 5,027 股。Charles Schwab Investment Management Inc. 在第三季度将其在 Cytokinetics 的股份增加了 42.7%。Charles Schwab Investment Management Inc. 目前拥有 1,321,391 股生物制药公司的股票，价值 69,769,000 美元，此前在上个季度又购买了 395,709 股。制造商人寿保险公司在第三季度将其在 Cytokinetics 的持股增加了 23.6%。制造商人寿保险公司目前拥有 214,832 股生物制药公司的股票，价值 11,343,000 美元，此前在上个季度又购买了 41,057 股。Cynosure Group LLC 在第三季度以 363,000 美元的价值购买了 Cytokinetics 的新股份。最后，MetLife Investment Management LLC 在第三季度将其在 Cytokinetics 的股份增加了 0.4%。MetLife Investment Management LLC 目前拥有 123,308 股生物制药公司的股票，价值 6,511,000 美元，此前在上个季度又购买了 538 股。</p>
</div><h2>Cytokinetics Trading Down 1.5 %</h2>
<div class="lb-trans"><h2>Cytokinetics 股价下跌 1.5%</h2>
</div><p>CYTK stock opened at $42.99 on Friday. Cytokinetics, Incorporated has a 52 week low of $40.53 and a 52 week high of $75.71. The company has a market cap of $5.09 billion, a price-to-earnings ratio of -7.99 and a beta of 0.95. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The business has a fifty day simple moving average of $45.80 and a 200-day simple moving average of $49.67.</p>
<div class="lb-trans"><p>周五，CYTK 股票开盘价为 42.99 美元。Cytokinetics, Incorporated 的 52 周低点为 40.53 美元，52 周高点为 75.71 美元。该公司的市值为 50.9 亿美元，市盈率为 -7.99，贝塔系数为 0.95。该公司的速动比率为 9.28，流动比率为 9.28，债务股本比率为 5.93。该公司的 50 日简单移动平均线为 45.80 美元，200 日简单移动平均线为 49.67 美元。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. On average, equities research analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current year.</p>
<div class="lb-trans"><p>Cytokinetics (NASDAQ:CYTK - 获取免费报告) 最近于 2 月 27 日星期四发布了季度财报。该生物制药公司报告本季度每股收益为（1.26 美元），超出分析师一致预期的（1.29 美元）0.03 美元。该公司本季度的收入为 1,693 万美元，而分析师预期为 1,426 万美元。平均而言，股票研究分析师预计 Cytokinetics, Incorporated 本年度将发布 -5.24 美元的每股收益。</p>
</div><h2>Insider Activity at Cytokinetics</h2>
<div class="lb-trans"><h2>Cytokinetics 内部活动</h2>
</div><p>In other news, EVP Andrew Callos sold 2,775 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.38, for a total value of $123,154.50. Following the transaction, the executive vice president now owns 34,888 shares of the company's stock, valued at approximately $1,548,329.44. This trade represents a 7.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert I. Blum sold 16,970 shares of Cytokinetics stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the transaction, the chief executive officer now owns 364,181 shares in the company, valued at $15,820,022.64. The trade was a 4.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,834 shares of company stock worth $1,949,275. Company insiders own 3.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Andrew Callos 于 3 月 17 日星期一出售了 2,775 股公司的股票。股票以平均价格 44.38 美元出售，总价值为 123,154.50 美元。交易后，执行副总裁现在拥有 34,888 股公司股票，价值约为 1,548,329.44 美元。这笔交易代表其持股减少了 7.37%。该出售在与 SEC 的法律文件中披露，文件可在此链接查看。此外，首席执行官 Robert I. Blum 于 3 月 6 日星期四出售了 16,970 股 Cytokinetics 股票。股票以平均价格 43.44 美元出售，总交易额为 737,176.80 美元。交易后，首席执行官现在拥有 364,181 股公司股票，价值 15,820,022.64 美元。这笔交易代表其持股减少了 4.45%。该出售的披露信息可在此处找到。在上个季度，内部人士共出售了 43,834 股公司股票，价值 1,949,275 美元。公司内部人士持有公司股票的 3.40%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts recently commented on CYTK shares. Evercore ISI raised shares of Cytokinetics to a &#34;strong-buy&#34; rating in a research note on Friday, February 7th. HC Wainwright reissued a &#34;buy&#34; rating and set a $120.00 price objective on shares of Cytokinetics in a research note on Friday, February 28th. JMP Securities reaffirmed a &#34;market outperform&#34; rating and issued a $78.00 target price on shares of Cytokinetics in a research note on Friday, February 7th. Morgan Stanley set a $67.00 price target on Cytokinetics in a research report on Friday, March 7th. Finally, Stifel Nicolaus assumed coverage on Cytokinetics in a report on Wednesday, January 22nd. They issued a &#34;buy&#34; rating and a $80.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $82.00.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 CYTK 股票发表了评论。Evercore ISI 在 2 月 7 日星期五的研究报告中将 Cytokinetics 的股票评级提高至 &#34;强力买入&#34;。HC Wainwright 在 2 月 28 日星期五的研究报告中重申了 &#34;买入&#34; 评级，并设定了 120.00 美元的目标价。JMP Securities 在 2 月 7 日星期五的研究报告中重申了 &#34;市场表现优于大盘&#34; 的评级，并对 Cytokinetics 设定了 78.00 美元的目标价。摩根士丹利在 3 月 7 日星期五的研究报告中设定了 Cytokinetics 的目标价为 67.00 美元。最后，Stifel Nicolaus 在 1 月 22 日星期三的报告中开始覆盖 Cytokinetics。他们给予了 &#34;买入&#34; 评级，并设定了 80.00 美元的目标价。两位股票研究分析师对该股票给予了持有评级，十五位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 82.00 美元。</p>
</div><p><strong>Read Our Latest Report on CYTK</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CYTK 的最新报告</strong></p>
</div><h2>Cytokinetics Company Profile</h2>
<div class="lb-trans"><h2>Cytokinetics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p>
<div class="lb-trans"><p>Cytokinetics, Incorporated 是一家处于后期阶段的生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗虚弱疾病的方案。该公司主要开发小分子药物候选者，旨在影响肌肉功能和收缩性。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cytokinetics</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>Energy and Oil Stocks Explained</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cytokinetics</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Penny Stock SurgePays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>能源和石油股票解析</li>
<li>三大饮料股票带来丰厚利润</li>
<li>选举股票：选举如何影响股市</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CYTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在细胞动力吗？</h2>
</div><p>Before you consider Cytokinetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑细胞动力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而细胞动力并不在名单上。</p>
</div><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Virtu Financial LLC 投资 303,000 美元于 Cytokinetics 公司（纳斯达克股票代码：CYTK）